These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 36410120)

  • 1. Zuogui-Jiangtang-Qinggan-Fang alleviates high-fat diet-induced type 2 diabetes mellitus with non-alcoholic fatty liver disease by modulating gut microbiome-metabolites-short chain fatty acid composition.
    Zou J; Xiang Q; Tan D; Shi L; Liu X; Wu Y; Yu R
    Biomed Pharmacother; 2023 Jan; 157():114002. PubMed ID: 36410120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Zuogui Jiangtang Qinggan Prescription promotes recovery of intestinal mucosal barrier in mice with type 2 diabetes mellitus and nonalcoholic fatty liver disease by improving intestinal flora homeostasis].
    Zou JJ; Li H; Zhou M; Huang QQ; Wu YJ; Yu R
    Zhongguo Zhong Yao Za Zhi; 2023 Jan; 48(2):525-533. PubMed ID: 36725242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver Lipidomics Analysis Revealed the Protective mechanism of Zuogui Jiangtang Qinggan Formula in type 2 diabetes mellitus with non-alcoholic fatty liver disease.
    Zhou M; Liu X; Wu Y; Xiang Q; Yu R
    J Ethnopharmacol; 2024 Jul; 329():118160. PubMed ID: 38588985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of Zuogui Jiangtang Qinggan Formula on lipid metabolism in db/db mouse model of type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease].
    Zhou M; Li L; Zou JJ; Liu X; Wu YJ; Xiang Q; Yu R
    Zhongguo Zhong Yao Za Zhi; 2024 Mar; 49(6):1587-1593. PubMed ID: 38621943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ling-Gui-Zhu-Gan decoction ameliorates nonalcoholic fatty liver disease via modulating the gut microbiota.
    Chen L-p; Zhang L-f; Liu S; Hua H; Zhang L; Liu B-c; Wang R-r
    Microbiol Spectr; 2024 Jun; 12(6):e0197923. PubMed ID: 38647315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Zuogui Jiangtang Qinggan Formula improves glucolipid metabolism in type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease by regulating FoxO1/MTP/APOB signaling pathway].
    Xiang YX; Huang YL; Zhou M; Zou JJ; Liu X; Liu ZY; Xiao F; Yu R; Xiang Q
    Zhongguo Zhong Yao Za Zhi; 2023 Aug; 48(16):4438-4445. PubMed ID: 37802870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. α-Lactalbumin peptide Asp-Gln-Trp alleviates hepatic insulin resistance and modulates gut microbiota dysbiosis in high-fat diet-induced NAFLD mice.
    Chen H; Sun Y; Zhao H; Qi X; Cui H; Li Q; Ma Y
    Food Funct; 2022 Oct; 13(19):9878-9892. PubMed ID: 36052713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatoprotective Effects of
    Jin W; Cho S; Laxi N; Bao T; Dai L; Yu H; Qi R; Zhang J; Ba G; Fu M
    Molecules; 2022 May; 27(10):. PubMed ID: 35630624
    [No Abstract]   [Full Text] [Related]  

  • 9. Tangshen formula targets the gut microbiota to treat non-alcoholic fatty liver disease in HFD mice: A 16S rRNA and non-targeted metabolomics analyses.
    Wang S; Li X; Zhang B; Li Y; Chen K; Qi H; Gao M; Rong J; Liu L; Wan Y; Dong X; Yan M; Ma L; Li P; Zhao T
    Biomed Pharmacother; 2024 Apr; 173():116405. PubMed ID: 38484559
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Huang Y; Cao J; Zhu M; Wang Z; Jin Z; Xiong Z
    Microbiol Spectr; 2024 Apr; 12(4):e0339323. PubMed ID: 38411057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice.
    Matsui M; Fukunishi S; Nakano T; Ueno T; Higuchi K; Asai A
    mBio; 2021 Aug; 12(4):e0115521. PubMed ID: 34225483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spinach consumption ameliorates the gut microbiota and dislipaemia in rats with diet-induced non-alcoholic fatty liver disease (NAFLD).
    Elvira-Torales LI; Periago MJ; González-Barrio R; Hidalgo N; Navarro-González I; Gómez-Gallego C; Masuero D; Soini E; Vrhovsek U; García-Alonso FJ
    Food Funct; 2019 Apr; 10(4):2148-2160. PubMed ID: 30938723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amlodipine, an anti-hypertensive drug, alleviates non-alcoholic fatty liver disease by modulating gut microbiota.
    Li Y; Zhao D; Qian M; Liu J; Pan C; Zhang X; Duan X; Zhang Y; Jia W; Wang L
    Br J Pharmacol; 2022 May; 179(9):2054-2077. PubMed ID: 34862599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
    Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
    Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Astragalus mongholicus polysaccharides ameliorate hepatic lipid accumulation and inflammation as well as modulate gut microbiota in NAFLD rats.
    Zhong M; Yan Y; Yuan H; A R; Xu G; Cai F; Yang Y; Wang Y; Zhang W
    Food Funct; 2022 Jul; 13(13):7287-7301. PubMed ID: 35726797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erchen Decoction alleviates obesity-related hepatic steatosis via modulating gut microbiota-drived butyric acid contents and promoting fatty acid β-oxidation.
    Zhang L; Chen N; Zhan L; Bi T; Zhou W; Zhang L; Zhu L
    J Ethnopharmacol; 2023 Dec; 317():116811. PubMed ID: 37336336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Desulfovibrio vulgaris, a potent acetic acid-producing bacterium, attenuates nonalcoholic fatty liver disease in mice.
    Hong Y; Sheng L; Zhong J; Tao X; Zhu W; Ma J; Yan J; Zhao A; Zheng X; Wu G; Li B; Han B; Ding K; Zheng N; Jia W; Li H
    Gut Microbes; 2021; 13(1):1-20. PubMed ID: 34125646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polysaccharide from Panax japonicus C.A. Mey prevents non-alcoholic fatty liver disease development based on regulating liver metabolism and gut microbiota in mice.
    Wu Y; Yin W; Hao P; Chen Y; Yu L; Yu X; Wu Y; Li X; Wang W; Zhou H; Yuan Y; Quan X; Yu Y; Hu B; Chen S; Zhou Z; Sun W
    Int J Biol Macromol; 2024 Mar; 260(Pt 1):129430. PubMed ID: 38228199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microbiota Dysbiosis and Gut Barrier Dysfunction Associated with Non-Alcoholic Fatty Liver Disease Are Modulated by a Specific Metabolic Cofactors' Combination.
    Quesada-Vázquez S; Bone C; Saha S; Triguero I; Colom-Pellicer M; Aragonès G; Hildebrand F; Del Bas JM; Caimari A; Beraza N; Escoté X
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated omics analysis unraveled the microbiome-mediated effects of Yijin-Tang on hepatosteatosis and insulin resistance in obese mouse.
    Lee JE; Lee SM; Jung J
    Phytomedicine; 2020 Dec; 79():153354. PubMed ID: 32992082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.